StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Ivabradine

HCID 132999
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
155974-00-8
Standard-SMILES
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2
InChIKey
ACRHBAYQBXXRTO-OAQYLSRUSA-N
Summenformel
C27H36N2O5
Durchschnittliche Molmasse
468,6 g/mol
Monoisotopische Masse
468,26242225

Überblick

Ivabradine is a member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Used (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure. It has a role as a cardiotonic drug. It is an aromatic ether, a benzazepine, a carbobicyclic compound and a tertiary amino compound. It is a conjugate base of an ivabradine(1+).

Namen und Bezeichner

Bevorzugter Name
Ivabradine
IUPAC
3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
Englischer Name
Ivabradine
Summenformel
C27H36N2O5
Molmasse
468.59

Namen und Synonyme

Ivabradine155974-00-8S-16257IvabradinaS 162573H48L0LPZQDTXSID20482403-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-oneCHEBI:85966s16257(S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one2H-3-Benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, (S)-
Weitere Namen anzeigen
Ivabradine sulfateIvabridine –Ivabradine APIIvabradine USP/EP/BPIvabradine HCl PremixN-desmethyl ivabridine-d6Ivabradine(Hydrochloride form)3-[3-[[(8S)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methyl-amino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
Ivabradinum3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one3-(3-(((8S)-3,4-dimethoxy-8-bicyclo(4.2.0)octa-1,3,5-trienyl)methyl-methylamino)propyl)-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one3-[3-[[(8S)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-oneRefChem:56735S162572S162602S 162572

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,4
Polarare Oberfläche (TPSA)
60,5 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
10
Schwere Atome
34
Formalladung
0
Komplexität
663

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 6 Einträge

Breast Feeding; Lactation; Milk, Human; Cardiovascular Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Endocrine DisruptorsPotential endocrine disrupting compound

Physikochemische Eigenschaften

Siedepunkt
626.9 · 626.9±55.0 °C(Predicted)
Dichte
1.146 · 1.146±0.06 g/cm3(Predicted)
pka
8.77 · 8.77±0.50(Predicted)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

HepatotoxicityIn large preregistration clinical trials, similar proportions of patients taking ivabradine as taking placebo developed ALT elevations [15% vs 17%] while ALT elevations above 5 times the upper limit of normal were uncommon [
Adverse EffectsThe most common adverse effects associated with ivabradine administration, according to the product label, include bradycardia, atrial fibrillation, hypertension, and phosphenes.
Toxicity SummarySigns and Symptoms of Overdose
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

C01EB17

C - Cardiovascular system

QC - Cardiovascular system

Protein Binding70% bound to plasma proteins.
Pharmacodynamics · 1 Eintrag

The funny channels (If) open during repolarization and close during depolarization, making ivabradine's activity dependent on heart rate or the closing and opening of the channels. Therefore ivabradine exhibits use-dependence and is more pharmacologically active at higher heart rates. Ivabradine exhibits a linear dose-dependent heart-rate lowering activity (bradycardic effect) until a maximum dose of 30-40mg. At higher doses, the concentration of ivabradine tends to plateau, reducing risk of serious sinus bradycardia. It has been shown that the metabolite of ivabradine lowers heart rate as well, contributing to ivabradine's overall effect.

Mechanism of Action · 1 Eintrag

Ivabradine lowers heart rate by selectively inhibiting If channels ("funny channels") in the heart in a concentration-dependent manner without affecting any other cardiac ionic channels (including calcium or potassium). Ivabradine binds by entering and attaching to a site on the channel pore from the intracellular side and disrupts If ion current flow, which prolongs diastolic depolarization, lowering heart rate. The If currents are located in the sinoatrial node and are the home of all cardiac pacemaker activity. Ivabradine therefore lowers the pacemaker firing rate, consequently lowering heart rate and reducing myocardial oxygen demand. This allows for an improved oxygen supply and therefore mitigation of ischemia, allowing for a higher exercise capacity and reduction in angina episodes.

Biological Half-Life2 hours.
Metabolism/Metabolites · 1 Eintrag

Ivabradine is extensively metabolized by oxidation in the gut and liver by cytochrome P450 3A4 enzyme. Its active metabolite, N-desmethylated derivative, is also metabolized by CYP 3A4. Ivabradine's affinity for CYP 3A4 is low, making it unlikely to affect the metabolism of other drugs; however potent inhibitors or inducers of CYP 3A4 may affect ivabradine's plasma concentration and pharmacodynamic effects and should not be co-administered.

Zugehörige Reaktionen

19
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 218987
HRID 218987als Produktals Edukt
Reaktionsgleichung von HRID 420869
HRID 420869als Produkt
Reaktionsgleichung von HRID 420870
HRID 420870als Produkt
Reaktionsgleichung von HRID 423132
HRID 423132als Produkt
Reaktionsgleichung von HRID 423133
HRID 423133als Edukt
Reaktionsgleichung von HRID 423134
HRID 423134als Produkt
Reaktionsgleichung von HRID 423135
HRID 423135als Edukt
Reaktionsgleichung von HRID 523523
HRID 523523als Edukt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
155974-00-8
PubChem CID
132999
DTXSID
DTXSID2048240
ChEMBL
CHEMBL471737
ChEBI
CHEBI:85966
UNII
3H48L0LPZQ
Nikkaji
J582.018I
FDA Pharmacological Classification · 6 Einträge

3H48L0LPZQ

IVABRADINE

Established Pharmacologic Class [EPC] - Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker

Mechanisms of Action [MoA] - Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists

Ivabradine is a Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker. The mechanism of action of ivabradine is as a Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonist.

IVABRADINE

MeSH Pharmacological ClassificationAgents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Absorption, Distribution and Excretion · 4 Einträge

It is recommended to take ivabradine with food to reduce variability in systemic exposure. Administration with food slows absorption by 1 hour, but increases systemic absorption by 20-30%. Ivabradine's oral bioavailability is about 40%.

Metabolites are equally excreted in feces and urine.

~100 L.

Total clearance is about 400ml/min; renal clearance about 70ml/min. About 4% is excreted unchanged in urine.

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >75
Anwendungen · 1 Eintrag

BeschreibungIvabradine is a first selective and specific If inhibitor that was approved by EMEA in November for symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm. This is the first agent to lower heart rate by inhibiting the cardiac pacemaker If current. The compound was discovered and developed by Servier and is currently being marketed in Ireland.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

3H-3-Benzazepine-3-propanal, 1,2,4,5-tetrahydro-7,8-dimethoxy-2-oxo-(S)-(4,5-diMethoxy-1,2-dihydrocyclobutabenzen-1-yl)-N-MethylMethanaMine3-[3-[[[(7S)-3,4-DiMethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]Methyl]MethylaMino]propyl]-1,3-dihydro-7,8-diMethoxy-H-3-benzazepin-2-one
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Use (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure.